Antenatal care service delivery and factors affecting effective tetanus vaccine coverage in low- and middle-income countries: Results of the Maternal Immunisation and Antenatal Care Situational analysis (MIACSA) project.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
14 07 2020
Historique:
received: 08 03 2020
revised: 04 05 2020
accepted: 07 05 2020
pubmed: 13 6 2020
medline: 28 4 2021
entrez: 13 6 2020
Statut: ppublish

Résumé

To map the integration of existing maternal tetanus immunization programmes within antenatal care (ANC) services for pregnant women in low- and middle-income countries (LMICs) and to identify and understand the challenges, barriers and facilitators associated with high performance maternal vaccine service delivery. A mixed methods, cross sectional study with four data collection phases including a desk review, online survey, telephone and face-to-face interviews and in country visits was undertaken between 2016 and 2018. Associations of different service delivery process components with protection at birth (PAB) and with country groups were established. PAB was defined as the proportion of neonates protected at birth against neonatal tetanus. Regression analysis and structural equation modelling was used to assess associations of different variables with maternal tetanus immunization coverage. Latent class analysis (LCA), was used to group country performance for maternal immunization, and to address the problem of multicollinearity. LMICs. The majority of LMICs had a policy on recommended number of ANC visits, however most were yet to implement the WHO guidelines recommending eight ANC contacts. Countries that recommended > 4 ANC contacts were more likely to have high PAB > 90%. Passive disease surveillance was the most common form of disease surveillance performed but the maternal and neonatal morbidity and mortality indicators recorded differed between countries. The presence of user fees for antenatal care and maternal immunization was significantly associated with lower PAB (<90%). Recommendations include implementing the current WHO ANC guideline to facilitate increased opportunities for vaccination during each pregnancy. Improved utilisation of ANC services by increasing the demand side by increasing the quality of services, reducing any associated costs and supporting user fee exemptions, or the supply side can also enhance utilisation of ANC services which are positioned as an ideal platform for delivery of maternal vaccines.

Identifiants

pubmed: 32527598
pii: S0264-410X(20)30644-7
doi: 10.1016/j.vaccine.2020.05.025
pmc: PMC7342001
pii:
doi:

Substances chimiques

Tetanus Toxoid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5278-5285

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

BMC Pregnancy Childbirth. 2014 Jun 13;14:204
pubmed: 24923284
Lancet Glob Health. 2019 Jun;7(6):e710-e720
pubmed: 31097275
BMJ Open. 2019 Jun 4;9(6):e024449
pubmed: 31167857
Lancet Glob Health. 2017 Oct;5(10):e977-e983
pubmed: 28911763
Can Commun Dis Rep. 2018 Mar 01;44(3-4):91-94
pubmed: 31007617
Vaccine. 2016 Nov 11;34(47):5785-5791
pubmed: 27742214
MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):131-5
pubmed: 23425962
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S200-S219
pubmed: 29117332
BJOG. 2018 Jan;125(2):140-147
pubmed: 28317228
Lancet. 2016 Feb 6;387(10018):587-603
pubmed: 26794078
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664

Auteurs

M L Giles (ML)

Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia. Electronic address: michelle.giles@monash.edu.

E Mason (E)

London School of Hygiene and Tropical Medicine, London, UK.

F M Muñoz (FM)

Section Infectious Diseases, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.

A C Moran (AC)

Epidemiology, Monitoring and Evaluation (EME), Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland.

P Lambach (P)

Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.

S Merten (S)

Swiss Tropical and Public Health Institute and University of Basel, Basel, Switzerland.

T Diaz (T)

Epidemiology, Monitoring and Evaluation (EME), Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland.

M Baye (M)

Coordinator of the National Program to Combat Maternal, Newborn and Child Mortality, Ministry of Public Health, Cameroon.

M Mathai (M)

Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

J Pathirana (J)

Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

S Rendell (S)

Department of Anthropology, University of Pennsylvania, Philadelphia, USA.

Ö Tunçalp (Ö)

Department of Sexual and Reproductive Health and Research Including UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland.

J Hombach (J)

Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.

N Roos (N)

Karolinska Institutet, Department of Medicine, Clinical Epidemiology Division, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH